WGc0201 for chronic hepatitis B
Part of Digestive system, Infections clinical trials.
This trial tests a new drug called WGc0201 in adults with chronic hepatitis B who have controlled their virus with standard antiviral pills. It aims to see if WGc0201 can further reduce hepatitis B surface antigen (HBsAg) levels.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 65 years old
- You have had hepatitis B for more than 6 months (HBsAg positive) and are currently taking a nucleoside analog antiviral pill like tenofovir or entecavir
- Your hepatitis B virus level (HBV-DNA) is under 100 IU/mL and your HBsAg level is below 1500 IU/mL
- You are not co-infected with HIV or hepatitis D, and do not have advanced liver scarring (cirrhosis) or liver failure
- You have no serious heart, lung, kidney, autoimmune, or other major diseases, and no history of liver cancer or organ transplant (except cornea or hair)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called HH-006 to see if it can help treat chronic hepatitis B infection. Participants will be grouped by their infection level, and the study checks whether the drug is safe and works to reduce the hepatitis B virus.
This trial tests a new drug called GST-HG141 for people with chronic hepatitis B whose virus is still active despite taking standard antiviral pills. It aims to see if the new drug can better control the virus.
This study tests an experimental injection called TVAX-008 for people with chronic hepatitis B who are already on antiviral therapy. It aims to see if it can help control the virus and potentially lead to a functional cure.
This trial tests a new treatment (GST-HG131&141 tablets) versus a placebo for people with chronic hepatitis B. It aims to see if the treatment can better control the virus in those already on stable therapy.
This trial tests a new drug, LW231, in people with chronic hepatitis B. It aims to see if the drug can reduce the amount of virus and surface antigen in your blood, and if it is safe for you.
This study tests a new drug, GST-HG131, for people with chronic hepatitis B who are already on stable treatment. It aims to see if the drug is safe and reduces the virus further.
Hear when a new Chronic Hepatitis B Virus (Hbv) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.